Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-123-0 | CAS number: 12070-12-1
Carcinogenicity
Administrative data
Description of key information
According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Justification for type of information:
- Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Link to relevant study records
- Endpoint:
- carcinogenicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Justification for type of information:
- Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Link to relevant study records
- Endpoint:
- carcinogenicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Justification for type of information:
- Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
No carcinogenicity data are available for tungsten carbide. Therefore, classification cannot be made due to lack of data
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
